Pfizer to Acquire Trillium for ~$2.26B
Shorts:
- Pfizer will acquire all outstanding shares of Trillium for $18.50/share in cash making a total equity value of $2.26B with 203.8% premium on the stock's last closing price
- The acquisition will bolster Pfizer’s R&D capabilities & accelerates clinical development of Trillium’s SIRPα fusion proteins i.e.- TTI-622 & TTI-621 that are currently in P-Ib/II trial for hematological malignancies
- In clinical studies- TTI-622 & TTI-621 demonstrated the activity as monothx. in r/r lymphoid malignancies- including DLBCL- PTCL- FL- & other lymphoid malignancies. Additionally- Trillium's biologics treatments will enhance patients innate immune systems to detect & destroy cancer cells
| Ref: Businesswire | Image: Trillium
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com